Why Is BRAVEHEART BIO INC (BRVE) Stock Up Today?

Why BRVE stock is up today

Braveheart Bio Inc stock surged 9.99% to $29.41 in morning trading on September 9, 2026, driven by a wave of new coverage from major Wall Street firms. The stock opened with a 0.9% gap up and reached a session high of $29.91 before settling near $29.41. Multiple analysts initiated coverage on the stock with positive ratings and price targets above the current price.

What Happened

The primary catalyst for the move was the initiation of coverage by several prominent firms. Goldman Sachs, TD Cowen, and Jefferies each began coverage with a Buy rating. Jefferies and Goldman Sachs both set a price target of $48, significantly above the current price. These actions followed Braveheart Bio’s report of second quarter 2026 financial results and a business update. The stock’s rally was also supported by recent insider buying activity, with three insiders including the Chief Development Officer and two directors purchasing shares on August 7. Additionally, the company has seen 10 insider buy transactions in the last 90 days totaling $159.0 million, with no insider sales reported.

What The Data Shows

The stock opened at $26.99 and traded as high as $29.91 during the session. It closed the session at $29.41, with 0.5 million shares changing hands. The stock has moved up 2.5% over the past eight sessions, from $27.86 to $28.56. On September 8, 2026, the stock printed 11 fresh 52-week highs. The stock currently trades within its 52-week range of $24.30 to $32.00 and has a market capitalization of $1.7 billion.

What To Watch

The stock is currently in a strong upward trend and has attracted positive analyst attention. Investors may want to monitor any further analyst commentary or developments from Braveheart Bio in the coming days.